<DOC>
	<DOCNO>NCT01523652</DOCNO>
	<brief_summary>The purpose study determine whether HGF serum concentration might raise vivo administer nadroparin give prophylactic purpose gynecological patient .</brief_summary>
	<brief_title>Pharmacokinetic Study Administration Nadroparin Dosing Serum HGF Gynecological Patients</brief_title>
	<detailed_description>The study consist two phase . In first phase , main HGF pharmacokinetic parameter evaluate , compare group six woman treat single dose calcic nadroparin control group six untreated woman . Venous blood drawn group 0 , 30 , 60 , 90 , 120 , 150 , 180 , 240 , 300 , 360 , 480 720 min . In second phase , HGF basal maximum concentration measure 17 woman , undergo one month calcic nadroparin daily treatment . Venous blood drawn twice day 1 ( 0 90 min nadroparin administration ) , day 8 28 ( 90 min LMWH injection ) . Calcic nadroparin give subcutaneously 2850 IU/0.3 ml anti-Xa . Patients ' characteristic : In first phase , 12 patient enrol , 6 treat nadroparin prophylactic anticoagulation another 6 untreated control group . The six nadroparin-group patient affect benign pelvic gynaecologic disease : three require laparoscopy three laparotomy . In control group , four healthy woman volunteer two patient submit gynaecological pelvic surgery , woman treat prophylactic LMWH . In second phase , 17 patient enrol among woman plan gynaecological pelvic surgery treat 4 week nadroparin prophylactic anticoagulation . All patient underwent laparotomy ; ten affected malignancy ( ECOC ) seven benign ( uterine fibroma , ovarian cystadenoma ) pelvic gynaecologic disease .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Urogenital Neoplasms</mesh_term>
	<mesh_term>Genital Diseases , Female</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<criteria>≥ 18 year ECOG PS ≤ 1 Neutrophils ≥ 1500 l 1 , platelet ≥ 150,000 l 1 , creatinine 0.6 1.2 mg dl 1 , total bilirubin ≤ 1 mg dL 1 , AST ≤ 35 U l1 , ALT ≤ 45 U l1 For patient study group : highmoderate risk deep vein thrombosis ( administration LMWH 30 day surgery ) general anesthesia &gt; 30 minute , laparoscopy + least one risk factor ( age &gt; 40 year , obesity , varicose vein , previous episode deep vein thrombosis / pulmonary thromboembolism , thrombophilia , malignancy , prolonged immobility , congestive heart failure ) severe liver renal disease diabetes hyperlipidemia mark osteoporosis HIV infection ongoing treatment : immunosuppressive therapy , contraceptive , lipidlowering drug , NSAIDs , antiplatelet drug , recent acute inflammatory infectious ( &lt; 3 week ) history allergy , drug possible confounding , caffeine , tobacco , ethanol ( must hire last 24 hour prior sample ) high risk bleeding : peptic ulcer , history hemorrhagic stroke , bleed disorder , severe hypertension , cerebral aneurysm , arteriovenous malformation , brain metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>